Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer
The Prostate · 02.08.2026
DOI: 10.1002/pros.70221 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Prostate, online erschienen am 02.08.2026. Verfasst von Lukas Scheipner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
Incidental prostate cancer (PCa) patients are currently stratified to either cT1a vs. cT1b stage, depending on tumor volume (< 5% vs. > 5%) in the resected tissue. We tested for other models that could improve cancer‐specific survival (CSS) predictions.
Methods
Incidental (cT1a/cT1b) PCa patients were retrospectively identified within the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). Kaplan–Meier plots illustrated CSS at 5 years of follow‐up. Combination of variables resulted in three distinct stratification models based on cT1a vs. cT1b and Gleason score sum (GS). Multivariable Cox regression models that predicted CSS were used for area under the curve (AUC) quantification after 20‐fold cross validation.
Results
We identified a total of 5155 incidental PCa patients. CSS at 5 years was 98% for cT1a vs. 90% for cT1b ( p < 0.0001). CSS at 5 years for combination of cT1a and GS 6 patients was 99% vs. 92% for patients with either cT1b or GS ≥ 7 ( p < 0.0001). Finally, for patients with GS < 8, CSS at 5 years was 98% vs. 72% for patients with GS ≥ 8 ( p < 0.0001). The multivariable adjusted AUC was 0.83 vs. 0.82 vs. 0.88, for each model, respectively.
Conclusion
Of all tested stratification models, the consideration of GS stratified between < 8 and ≥ 8 resulted in the best survival discrimination, as well as highest accuracy after cross‐validation. In consequence, the use of this model (GS < 8 vs. ≥ 8) appears better suited than the standard cT1a vs. cT1b substaging, when CSS represents the endpoint of interest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
- Department of Urology, Medical University of Graz, Graz, Austria.
- Department of Urology, IRCCS Policlinico San Donato, Milan, Italy.
- Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
- Università degli Studi di Milano, Milan, Italy.
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
ORCID-Profile: Nicola Longo
Zitieren
APA
Scheipner, L., Baudo, A., Jannello, L. M. I., Siech, C., Angelis, M., Bello, F. D., Tian, Z., Saad, F., Shariat, S. F., Briganti, A., Chun, F. K. H., Carmignani, L., Cobelli, O., Longo, N., Mischinger, J., Ahyai, S., & Karakiewicz, P. I. (2026). Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70221
Vancouver
Scheipner L, Baudo A, Jannello LMI, Siech C, Angelis M, Bello FD, et al. Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer. The Prostate. 2026. doi:10.1002/pros.70221
BibTeX
@article{Scheipner2026,
author = {Scheipner, Lukas and Baudo, Andrea and Jannello, Letizia Maria Ippolita and Siech, Carolin and Angelis, Mario de and Bello, Francesco Di and Tian, Zhe and Saad, Fred and Shariat, Shahrokh F and Briganti, Alberto and Chun, Felix K H and Carmignani, Luca and Cobelli, Ottavio De and Longo, Nicola and Mischinger, Johannes and Ahyai, Sascha and Karakiewicz, Pierre I},
title = {Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70221}
}
EUVIMED